How to buy Cyclacel Pharmaceuticals stock (CYCC)

Cyclacel Pharmaceuticals is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.32 – a decrease of 12.1% over the previous week.

Our top picks for where to buy Cyclacel Pharmaceuticals stock

Buy Cyclacel Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cyclacel Pharmaceuticals stock price (NASDAQ: CYCC)

Use our graph to track the performance of CYCC stocks over time.

Cyclacel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.32
52-week range	$0.32 - $4.00
50-day moving average more info button	$0.58
200-day moving average more info button	$1.44
Wall St. target price	$1.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-27.40

Is it a good time to buy Cyclacel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclacel Pharmaceuticals price performance over time

Historical closes compared with the close of $0.331 from 2024-12-19

1 week (2024-12-13)	-8.34%
1 month (2024-11-21)	-4.69%
3 months (2024-09-20)	-66.22%
6 months (2024-06-21)	-81.09%

1 year (2023-12-21)	-90.81%
2 years (2022-12-21)	-96.89%
3 years (2021-12-21)	54.45
5 years (2019-12-20)	157.98

Cyclacel Pharmaceuticals financials

Revenue TTM	$80,000
Gross profit TTM	$-455,000
Return on assets TTM	-102.53%
Return on equity TTM	-570.69%
Profit margin	0%
Book value	$0.57
Market Capitalization more info button	$2.1 million

TTM: trailing 12 months

Cyclacel Pharmaceuticals share dividends

We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.

Have Cyclacel Pharmaceuticals's shares ever split?

Cyclacel Pharmaceuticals's shares were split on a 1:15 basis on 17 December 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.

Cyclacel Pharmaceuticals share price volatility

Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $0.3241 up to $4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 0.557. This would suggest that Cyclacel Pharmaceuticals's shares are less volatile than average (for this exchange).

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. .

Frequently asked questions

null
What percentage of Cyclacel Pharmaceuticals is owned by insiders or institutions?
Currently 4.816% of Cyclacel Pharmaceuticals shares are held by insiders and 18.026% by institutions. When does the fiscal year end for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals's fiscal year ends in December. Where is Cyclacel Pharmaceuticals based?
Cyclacel Pharmaceuticals's address is: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 What is Cyclacel Pharmaceuticals's ISIN number?
Cyclacel Pharmaceuticals's international securities identification number is: US23254L6039 What is Cyclacel Pharmaceuticals's CUSIP number?
Cyclacel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 23254L603